MedTrace Logo

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis

NCT04341454 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 327

Last updated 2021-12-21

No results posted yet for this study

Summary

The purpose of study is to confirm the efficacy of DWP14012 X mg QD, DWP14012 Y mg BID compared to placebo in patients with Acute or Chronic Gastritis

Conditions

  • Acute Gastritis
  • Chronic Gastritis

Interventions

DRUG

DWP14012 X mg

DWP14012 X mg, tablet, orally, once daily for 2 weeks

DRUG

DWP14012 X mg placebo

DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks

DRUG

DWP14012 Y mg

DWP14012 Y mg, tablet, orally, twice daily for 2 weeks

DRUG

DWP14012 Y mg placebo

DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-02
Primary Completion
2021-08-04
Completion
2021-09-16

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341454 on ClinicalTrials.gov